Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquilin-3 (UBQLN3) is a ubiquitin-like protein specifically expressed in the testis and shares significant sequence similarity with other ubiquilin family members (UBQLN1, UBQLN2, and UBQLN4). It contains an N-terminal ubiquitin-like (UBL) domain and a C-terminal ubiquitin-associated (UBA) domain, enabling it to physically associate with proteasomes and ubiquitin ligases. UBQLN3 is thought to link the ubiquitination machinery to the proteasome and facilitate in vivo protein quality control and degradation—particularly in the context of spermatogenesis. Functional studies in mice showed UBQLN3 is dispensable for embryonic development and spermatogenesis; currently, its precise biological role remains less characterized compared to UBQLN1, UBQLN2, and UBQLN4. Disease associations are limited, with some links to azoospermia and X-linked spinal muscular atrophy, but no established role in major neurodegenerative diseases or cancer like other ubiquilins. The broader ubiquilin family is involved in diverse functions including facilitating degradation via the ubiquitin-proteasome system (UPS), autophagy, endoplasmic-reticulum-associated degradation (ERAD), and acting as molecular chaperones for misfolded proteins. However, the testis-specific expression and uncertain impact on disease or therapeutic intervention distinguish UBQLN3 from more widely studied family members.
None identified for drugs targeting this molecule
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquilin-3 (UBQLN3).